Live price temporarily unavailable.
CytomX Therapeutics (CTMX) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $15.0M | $71.6M | $59.5M | $26.9M | $68.4M | $37.3M | $53.2M | $101.2M | $138.1M | $76.2M |
| Growth (year over year) | +95.1% | +376.1% | −16.9% | −54.8% | +154.4% | −45.5% | +42.5% | +90.4% | +36.4% | −44.8% |
| Operating income | −$59.6M | −$46.3M | −$77.9M | −$141.5M | −$80.5M | −$116.0M | −$101.3M | −$6.48M | $25.0M | −$22.4M |
| Operating margin | −396.1% | −64.6% | −130.9% | −525.9% | −117.7% | −311.0% | −190.6% | −6.4% | 18.1% | −29.3% |
| Net income | −$58.9M | −$43.1M | −$84.6M | −$132.8M | −$64.8M | −$115.9M | −$99.3M | −$569.0K | $31.9M | −$17.4M |
| Net margin | −391.5% | −60.2% | −142.2% | −493.7% | −94.7% | −310.5% | −186.8% | −0.6% | 23.1% | −22.8% |
| EPS (diluted) | −$1.63 | −$1.16 | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||||
| Cash and equivalents | $104.6M | $177.5M | $247.6M | $188.4M | $191.9M | $205.5M | $193.7M | $17.2M | $38.1M | $12.7M |
| Total assets | $199.1M | $397.6M | $457.1M | $341.3M | $358.7M | $339.4M | $260.9M | $201.8M | $120.5M | $151.6M |
| Total liabilities | $120.6M | $327.7M | $326.2M | $290.2M | $366.4M | $339.9M | $346.6M | $249.2M | $121.0M | $52.6M |
| Shareholders' equity | $78.5M | $69.9M | $135.8M | $25.5M | −$7.77M | −$459.0K | −$85.8M | −$47.4M | −$456.0K | $99.0M |
| Cash flow | ||||||||||
| Operating cash flow | −$2.03M | $170.4M | −$75.5M | −$140.5M | $5.26M | −$119.0M | −$110.8M | −$56.0M | −$86.2M | −$75.6M |
| Capital expenditure | $2.18M | $1.56M | $3.79M | $3.50M | $2.31M | $1.61M | $1.74M | $840.0K | $310.0K | $220.0K |
| Free cash flow | −$4.21M | $168.8M | −$79.3M | −$144.0M | $2.95M | −$120.6M | −$112.5M | −$56.9M | −$86.5M | −$75.8M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $33.4M | $38.1M | $50.9M | $18.7M | $5.96M | — | $10.3M | $1.42M |
| Growth (year over year) | +26.7% | +43.2% | +22.8% | −25.7% | −82.2% | — | −79.9% | −92.4% |
| Operating income | $4.11M | $17.7M | $22.6M | −$1.29M | −$15.8M | — | −$19.7M | −$23.8M |
| Operating margin | 12.3% | 46.4% | 44.4% | −6.9% | −264.4% | — | −191.8% | −1677.1% |
| Net income | $5.74M | $18.9M | $23.5M | −$154.0K | −$14.2M | — | −$18.2M | −$20.7M |
| Net margin | 17.2% | 49.6% | 46.2% | −0.8% | −238.6% | — | −177.9% | −1457.4% |
| Balance sheet | ||||||||
| Cash and equivalents | $40.6M | $38.1M | $47.6M | $49.0M | $34.2M | $12.7M | $28.8M | $17.2M |
| Total assets | $139.0M | $120.5M | $98.5M | $175.1M | $158.3M | $151.6M | $359.4M | $381.2M |
| Total liabilities | $162.4M | $121.0M | $73.4M | $55.1M | $50.9M | $52.6M | $39.4M | $79.2M |
| Shareholders' equity | −$23.5M | −$456.0K | $25.0M | $119.9M | $107.4M | $99.0M | $319.9M | $302.1M |
| Cash flow | ||||||||
| Operating cash flow | −$20.7M | −$19.9M | −$21.0M | −$15.8M | −$15.5M | — | −$25.5M | −$18.1M |
| Capital expenditure | $19.0K | $80.0K | $119.0K | $27.0K | −$127.0K | — | $0 | $0 |
| Free cash flow | −$20.7M | −$20.0M | −$21.2M | −$15.8M | −$15.4M | — | −$25.5M | −$18.1M |
From CytomX Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning CytomX Therapeutics in our feed yet.